Olio Labs vs Veeva Systems
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF AI drug discovery company identifying multi-protein combination therapeutics 4x faster at 90% lower cost; YC S23 $4.5M Boom Capital Series A with in vivo/vitro results competing with Recursion for combination therapy AI.
About
Olio Labs is a San Francisco-based computational drug discovery company using AI and machine learning to identify multi-protein combination therapeutics for complex diseases — targeting biological pathways where single-target drugs fail because the disease involves multiple protein interactions simultaneously. Founded in 2023 and backed by Y Combinator (S23) with $5 million raised including a $4.5 million Series A led by Boom Capital and Overwater Ventures in March 2025, Olio Labs' combination therapeutics platform has demonstrated in vivo and in vitro superiority over existing market drugs, with a discovery process claimed to be 4x faster and 90% lower cost than traditional drug development approaches.
Veeva Systems (VEEV) reported $2.7B revenue in FY2025, up 14% YoY. #1 cloud platform for life sciences. ~8,000 employees. HQ: Pleasanton, CA. Market cap ~$40B.
About
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executive) and Matt Wallach, Veeva built its platform on Salesforce and later developed its own Vault cloud infrastructure. The company became a public benefit corporation (PBC) in 2021. Veeva reported revenues of $2.7B in fiscal year 2025 (ending January 2025), up 14% year-over-year, with a market capitalization of approximately $40B.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.